Added to YB: 2026-04-29
Pitch date: 2026-04-24
GSK [neutral]
GSK plc
+0.5%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 80.6B
Pitch Price
GBP 20.18
Price Target
N/A
Dividend
3.56%
EV/EBITDA
8.19
P/E
14.55
EV/Sales
2.90
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 24/4/2026 - GSK – Pipeline progress
GSK (update): Blenrep approved in China for 2L+ relapsed/refractory multiple myeloma (30k annual cases vs 180k global). Already approved in 15+ markets (EU, UK, Japan, Canada). New Phase II trial for uncomplicated malaria. Pipeline expansion broadening addressable market. Trades 10.6x 2027 EPS vs peers, 3.7% yield.
Read full article (1 min)